LB Pharmaceuticals, Inc. (LBRX)
NASDAQ:LBRX
Want to see LBRX full AI Analyst Report?
Top Page
LB Pharmaceuticals, Inc.
(NASDAQ:LBRX)
Select Model
Select Model
Rating:61Neutral
Price Target:
$32.00
▲(4.85% Upside)
Action:Reiterated
Date:04/18/26
The score is driven primarily by weak fundamentals typical of an early-stage biotech (no revenue, ongoing losses and cash burn), partially offset by a notably strengthened balance sheet and additional financing. Technicals are strong with positive momentum, while valuation remains constrained by losses and the absence of a dividend.
Positive Factors
Strong balance sheet
The material 2025 equity turnaround and light leverage provide durable financial flexibility to fund clinical programs and absorb near-term setbacks. With a substantially larger asset base and minimal debt, the company faces lower immediate solvency risk, enabling multi-month to multi-quarter execution of R&D plans without immediate forced distress financing.
Negative Factors
No revenue, sustained losses
As an early-stage biotech with no commercial revenue, LB Pharmaceuticals remains wholly dependent on successful clinical outcomes to create a durable revenue stream. Persistent losses mean the company cannot self-fund operations long-term; until regulatory approval or licensing revenue occurs, the business model inherently depends on external funding and milestone-dependent progress.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong balance sheet
The material 2025 equity turnaround and light leverage provide durable financial flexibility to fund clinical programs and absorb near-term setbacks. With a substantially larger asset base and minimal debt, the company faces lower immediate solvency risk, enabling multi-month to multi-quarter execution of R&D plans without immediate forced distress financing.
Read all positive factors
LB Pharmaceuticals, Inc. (LBRX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$795.49M
Dividend YieldN/A
Average Volume (3M)239.05K
Price to Earnings (P/E)―
Beta (1Y)1.59
Revenue GrowthN/A
EPS Growth35.45%
CountryUS
Employees16
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding28,676,653
10 Day Avg. Volume318,803
30 Day Avg. Volume239,047
Financial Highlights & Ratios
PEG Ratio0.24
Price to Book (P/B)1.87
Price to Sales (P/S)0.00
P/FCF Ratio-15.97
Enterprise Value/Market Cap0.58
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-5.67K
Enterprise Value/Ebitda-10.06
Forecast
1Y Price Target
$47.20Price Target Upside54.65% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
LB Pharmaceuticals, Inc. Business Overview & Revenue Model
Company Description
Clinical‑stage biopharmaceutical company developing novel therapies for neuropsychiatric diseases (e.g. schizophrenia, bipolar depression). Lead candidate is LB‑102, a methylated derivative of amisulpride....
How the Company Makes Money
null...
LB Pharmaceuticals, Inc. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
56
Neutral
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -82.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -46.19M | -30.08M | -63.01M | -1.45M | -12.19M |
| Net Income | -39.17M | -25.20M | -63.10M | -6.28M | -14.35M |
Balance Sheet | |||||
| Total Assets | 393.48M | 312.93M | 33.53M | 45.66M | 21.49M |
| Cash, Cash Equivalents and Short-Term Investments | 365.64M | 295.21M | 28.00M | 43.29M | 21.40M |
| Total Debt | 3.47M | 3.57M | 3.70M | 0.00 | 24.15M |
| Total Liabilities | 14.79M | 11.62M | 128.09M | 80.13M | 50.30M |
| Stockholders Equity | 378.69M | 301.31M | -94.55M | -34.47M | -28.81M |
Cash Flow | |||||
| Free Cash Flow | -51.71M | -35.26M | -53.82M | -12.12M | -2.73M |
| Operating Cash Flow | -51.63M | -35.21M | -53.05M | -12.09M | -2.73M |
| Investing Cash Flow | -42.41M | -39.89M | 23.23M | -28.01M | 123.00K |
| Financing Cash Flow | 396.39M | 302.56M | 38.31M | 33.68M | 22.96M |
LB Pharmaceuticals, Inc. Risk Analysis
LB Pharmaceuticals, Inc. disclosed 85 risk factors in its most recent earnings report. LB Pharmaceuticals, Inc. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 1 New Risks
1.
condition or results of operations, which may adversely affect investor confidence in us and, as a result, the value of our common stock. Q1, 2026
LB Pharmaceuticals, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
LBRX
LB Pharmaceuticals, Inc.
27.27
10.47
62.32%
HIND
Vyome Holdings
2.01
-21.67
-91.51%
ENVB
Enveric Biosciences
2.11
-14.09
-86.98%
PBM
Psyence Biomedical
3.91
-29.34
-88.24%
SPRC
SciSparc Ltd.
4.55
-56.18
-92.51%
LB Pharmaceuticals, Inc. Corporate Events
Executive/Board Changes
LB Pharmaceuticals Announces Director Zachary Prensky’s Planned Retirement
Neutral
Mar 16, 2026
On March 13, 2026, LB Pharmaceuticals, Inc. announced that director Zachary Prensky plans to retire from the Board and will not stand for reelection at the 2026 annual meeting of stockholders, with his term ending at that meeting. The company emph...
Business Operations and StrategyExecutive/Board Changes
LB Pharmaceuticals adds neuroscience leader to board, governance
Positive
Mar 10, 2026
On March 6, 2026, LB Pharmaceuticals appointed veteran neuroscience drug development executive Robert A. Lenz, M.D., Ph.D., to its Board of Directors as a Class I director and member of the Nominating and Corporate Governance Committee, compensati...
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
LB Pharmaceuticals Announces $100 Million Private Placement Financing
Positive
Feb 5, 2026
On February 4, 2026, LB Pharmaceuticals entered into a securities purchase agreement with a group of institutional investors for a $100 million private placement comprising 3,306,571 shares of common stock and pre-funded warrants to purchase up to...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.